Searched for
EMCURE PHARMA
Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Stocks in news: Paytm, Bajaj Auto, L&T, Bharti Airtel, Hero MotoCorpMarkets closed lower amid global headwinds and geopolitical worries. Several companies like Paytm, Bajaj Auto, and L&T are in focus due to ...
- Emcure eyes India growth, global deals amid strong demandEmcure Pharmaceuticals is boosting domestic expansion, R&D, and manufacturing. The company is also exploring acquisition opportunities in I...
- Adani Ports, Tata Motors and Siemens Energy witness block deal action on MondayInstitutional investors injected over Rs 7,400 crore into Adani Ports and Special Economic Zone (APSEZ) on Monday through significant block...
- Mauritius-based entity sells Rs 289 crore worth shares in Emcure Pharmaceuticals via block deal; Norges Bank acquirerEmcure Pharmaceuticals saw a significant block deal where BC Investments IV Limited sold 18 lakh shares for Rs 289 crore to Norges Bank. Th...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Narendra Solanki sees limited IT growth, bets on rural and pharma playsInvestors are becoming selective, focusing on earnings visibility and strong balance sheets. Opportunities are emerging in sectors like IT,...
- Emcure cuts semaglutide injection price by average 47%The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pe...
- Emcure slashes prices of weight management drug Poviztra by up to 55%Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...
- Emcure Pharma shares in focus after GST Department conducts search at Mumbai officesEmcure Pharmaceuticals' shares could see action following a Goods and Services Tax search at its Mumbai offices. The inspection concluded t...
- Emcure Pharma Q2 profit rises 25%, revenue up 13% on broad-based growthPune-based Emcure Pharmaceuticals reported a 13.4% year-on-year rise in consolidated revenue to ₹2,270 crore in the September quarter, supp...
- Stocks in news: TCS, Akzo Nobel, Indosolar, Emcure Pharma, Enviro InfraMarkets experienced volatility within a tight range, closing slightly lower, continuing the consolidation trend. TCS is set to release its ...
- Emcure Pharma shares advance 10% as Kotak Equities sees 28% upside in stockDriven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal chall...
- Emcure Pharma shares jump over 4% post listing. Should you buy, sell or hold?Pune-based Emcure Pharmaceuticals listed at Rs 1,325, a 31.4% premium on Rs 1,008 IPO price. QIBs subscribed 195.8 times, non-institutional...
- Emcure Pharma shares debut with 31% premium over issue priceBefore listing, the company's shares traded at a Rs 360 premium in the grey market. It raised Rs 582 crore from anchor investors, including...
- Namita Thapar-backed Emcure Pharma IPO opens for subscription. Should you bid?Emcure Pharma IPO: Emcure Pharmaceuticals IPO, with marquee investors like Goldman Sachs, offers a fresh equity issuance and OFS. Namita Th...
- Shark tank fame Namita Thapar to rake in Rs 127 crore through Emcure Pharma IPOShark Tank's Namita Thapar, who is part of Emcure Pharmaceuticals' promoter group, is set to earn approximately Rs 127 crore through the up...
- Blackstone to sell its stake in Emcure Pharma to Bain CapitalPrivate equity major Blackstone is selling its stake in Pune-based Emcure Pharmaceuticals to Bain Capital.
Load More
